This month, The Fass Lane discusses the results of a study assessing the difference between potassium-competitive acid blockers and proton pump inhibitors with respect to short-term adverse events.

The FDA has approved lirafugratinib (Lyrfigtu, Elevar) for the treatment of adults with previously treated unresectable, locally advanced, or metastatic cholangiocarcinoma harboring a fibroblast ...

In this installment of our video series Through the Scope, Rajesh Keswani, MD, MS, demonstrates the importance of careful ...

Being diagnosed with inflammatory bowel disease often leads to isolation, shame, and a lot of potentially embarrassing questions.

Higher preoperative abundance of the periodontal pathogenic bacterium Porphyromonas was associated with an increased risk for recurrence in patients with early-stage colorectal cancer undergoing ...

Two leaders at the forefront of fellowship curriculum design met with GEN recently to discuss the pros and cons shortening ...

This edition of The Regueiro Report explores whether proactively monitoring fecal calprotectin in adults with ulcerative colitis in remission lowers their chance of experiencing symptomatic flares.

A sharp increase in the demand for endoscopic services portends a looming staffing shortage, but a national standardized training program for endoscopy technicians aims to address this impending ...

A survey is an open-book test. There should not be any surprises as far as what we’re looking at, what we’re looking for, or what our approach is going to be. Joint Commission uses a tracer ...

These email addresses will only be used to send out this message.

In this installment of Expert Picks from the Society of Gastroenterology Nurses and Associates 2026 Annual Course, Cynthia M. Friis, MEd, BSN, RN, NPD-BC, the associate executive director of clinical ...